$652 Million is the total value of Kynam Capital Management, LP's 31 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 43.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | New | HORIZON THERAPEUTICS PUB L | $125,180,000 | – | 1,100,000 | +100.0% | 19.20% | – |
| NTRA | Buy | NATERA INC | $104,570,825 | +18.2% | 2,603,207 | +29.0% | 16.04% | -13.9% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $71,552,232 | +59.1% | 1,605,390 | +0.3% | 10.98% | +15.8% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $65,182,209 | +19.3% | 2,561,187 | +12.7% | 10.00% | -13.1% |
| PCVX | Buy | VAXCYTE INC | $33,729,996 | +101.2% | 703,441 | +0.7% | 5.17% | +46.4% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $30,223,499 | +47.4% | 1,034,697 | +3.5% | 4.64% | +7.3% |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $27,809,000 | -12.0% | 100,000 | -33.8% | 4.27% | -36.0% |
| VERA | Sell | VERA THERAPEUTICS INCcl a | $27,266,046 | -16.7% | 1,409,098 | -8.3% | 4.18% | -39.4% |
| CNCE | Buy | CONCERT PHARMACEUTICALS INC | $25,814,838 | +130.3% | 4,420,349 | +164.2% | 3.96% | +67.7% |
| Buy | GSK PLCsponsored adr | $17,627,735 | +19.8% | 501,643 | +0.3% | 2.70% | -12.8% | |
| BNR | Buy | BURNING ROCK BIOTECH LTDsponsored ads | $16,631,057 | +3.8% | 7,391,581 | +10.3% | 2.55% | -24.4% |
| APLS | New | APELLIS PHARMACEUTICALS INC | $15,513,000 | – | 300,000 | +100.0% | 2.38% | – |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $11,667,110 | +59.3% | 9,642,240 | +43.5% | 1.79% | +15.9% |
| LQDA | Buy | LIQUIDIA CORPORATION | $11,165,597 | +21.3% | 1,752,841 | +3.6% | 1.71% | -11.7% |
| COGT | Sell | COGENT BIOSCIENCES INC | $9,179,206 | -37.6% | 794,049 | -19.4% | 1.41% | -54.5% |
| TVTX | Buy | TRAVERE THERAPEUTICS INC | $8,792,622 | -14.4% | 418,099 | +0.3% | 1.35% | -37.7% |
| WVE | Sell | WAVE LIFE SCIENCES LTD | $8,667,274 | +71.8% | 1,238,182 | -11.4% | 1.33% | +25.1% |
| MRTX | New | MIRATI THERAPEUTICS INC | $8,661,369 | – | 191,158 | +100.0% | 1.33% | – |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $5,683,259 | +29.8% | 520,922 | +0.3% | 0.87% | -5.4% |
| OLMA | Buy | OLEMA PHARMACEUTICALS INC | $4,961,823 | +28.4% | 2,025,234 | +44.7% | 0.76% | -6.5% |
| MCRB | Buy | SERES THERAPEUTICS INC | $4,349,307 | -12.3% | 776,662 | +0.5% | 0.67% | -36.2% |
| GOSS | Buy | GOSSAMER BIO INC | $3,844,253 | -16.9% | 1,771,545 | +358.5% | 0.59% | -39.5% |
| STRO | New | SUTRO BIOPHARMA INC | $3,268,716 | – | 404,544 | +100.0% | 0.50% | – |
| ALLO | New | ALLOGENE THERAPEUTICS INC | $2,493,218 | – | 396,378 | +100.0% | 0.38% | – |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $2,375,606 | +79.0% | 561,609 | +0.3% | 0.36% | +30.0% |
| CNTA | Buy | CENTESSA PHARMACEUTICALS PLCsponsored ads | $2,275,171 | -22.6% | 733,926 | +0.3% | 0.35% | -43.7% |
| CABA | Sell | CABALETTA BIO INC | $1,530,746 | +346.3% | 165,486 | -68.6% | 0.24% | +226.4% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $1,139,014 | +9.6% | 28,887 | +0.3% | 0.18% | -20.1% |
| CNTB | CONNECT BIOPHARMA HLDGS LTDads | $641,867 | -32.7% | 739,649 | 0.0% | 0.10% | -51.2% | |
| NLTX | Buy | NEOLEUKIN THERAPEUTICS INC | $61,469 | -20.2% | 120,764 | +0.3% | 0.01% | -43.8% |
| CBIO | Buy | CATALYST BIOSCIENCES INC | $47,730 | +6.1% | 90,484 | +0.3% | 0.01% | -22.2% |
| LQDA | Exit | LIQUIDIA CORPORATIONcall | $0 | – | -507,700 | -100.0% | -0.00% | – |
| TCDA | Exit | TRICIDA INCput | $0 | – | -97,600 | -100.0% | -0.03% | – |
| TCDA | Exit | TRICIDA INCcall | $0 | – | -260,000 | -100.0% | -0.07% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INCput | $0 | – | -300,000 | -100.0% | -0.17% | – |
| AFMD | Exit | AFFIMED N V | $0 | – | -676,675 | -100.0% | -0.29% | – |
| AKUS | Exit | AKOUOS INC | $0 | – | -718,394 | -100.0% | -1.02% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS INC | $0 | – | -435,117 | -100.0% | -1.16% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -676,849 | -100.0% | -1.49% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -131,220 | -100.0% | -1.88% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -75,000 | -100.0% | -4.22% | – |
| SNY | Exit | SANOFIsponsored adr | $0 | – | -600,000 | -100.0% | -4.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 12.3% |
| CELLDEX THERAPEUTICS INC NEW | 8 | Q3 2023 | 14.4% |
| VAXCYTE INC | 8 | Q3 2023 | 10.9% |
| VERA THERAPEUTICS INC | 8 | Q3 2023 | 6.9% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 7.6% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 4.6% |
| BURNING ROCK BIOTECH LTD | 8 | Q3 2023 | 3.4% |
| AMARIN CORP PLC | 8 | Q3 2023 | 4.0% |
| LIQUIDIA CORPORATION | 8 | Q3 2023 | 3.6% |
| WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 3.7% |
View Kynam Capital Management, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-03-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-01-10 |
View Kynam Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.